ArticleClinics and practice2024
Predictors of Readmission in Young Adults with First-Episode Psychosis: A Multicentric Retrospective Study with a 12-Month Follow-Up.
Article in Clinics and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effects of positive psychology theory in the rehabilitation nursing of Chinese patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2025Pooled it
- An observational study on the effects of as-needed use of various antipsychotic drugs for agitation due to psychotic disorders.International clinical psychopharmacology · 2026Observational
- Impact of community mental health center follow-up on psychiatric hospitalization burden in schizophrenia spectrum disorders: a retrospective mirror-image study.BMC psychiatry · 2026Article
- Cost Burden, Readmission Dynamics, and Service Management in Psychiatric Care: A Financial Performance Analysis in a Romanian Public Hospital.Healthcare (Basel, Switzerland) · 2026Article
- Adaptation of the "Osnabrück Scale for Therapy Adjustment and Identification of Psychological Complaints in Schizophrenia-OSSTI-TR" into Turkish culture and investigation of its psychometric characteristics.Frontiers in psychiatry · 2026Article
- Interleukin-5, Eosinophil, and Immunoglobulin A Levels in Schizophrenia Patients.Alpha psychiatry · 2025Article
- Long-Acting Injectable Antipsychotic Use in Children and Adolescents in Comparison to Adults.Journal of clinical medicine · 2025Article
- A CNN-Transformer Fusion Model for Proactive Detection of Schizophrenia Relapse from EEG Signals.Bioengineering (Basel, Switzerland) · 2025Article
- Two-Injection Start Regimen of Long-Acting Injectable Aripiprazole: Retrospective Data From a Tertiary Care Hospital in Turkey.Alpha psychiatry · 2025Article
- Evaluation of Prescription Patterns of Antipsychotics in Schizophrenia Patients-A Single-Center Prospective Study.Journal of clinical medicine · 2025Article
- Uric acid and HDL-C-derived inflammatory ratios as biomarkers in schizophrenia and major depressive disorder: a retrospective study.Frontiers in psychiatry · 2025Article
- Acceptance level and influencing factors of advance care planning among patients with schizophrenia in China: a cross-sectional survey.Frontiers in psychiatry · 2025Article
- Real-world examination of the rates of long-acting injectable attrition in a cohort of early psychosis patients after discharge from an early intervention service for psychosis.Therapeutic advances in psychopharmacology · 2025Article
- Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia.Frontiers in psychiatry · 2025Article
- Optimizing long-acting injectable antipsychotic safety and care continuity through documentation best practices.Frontiers in psychiatry · 2025Review
- Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.Neuropsychiatric disease and treatment · 2025Article
- Long-term effectiveness, adherence and safety of twice-yearly paliperidone-palmitate long acting-injectable in patients with schizophrenia in Europe: 2-year mirror-image data from the paliperdone-2 per year study (P2Y).Frontiers in psychiatry · 2025Article
- Critical Analysis of Tools for Measuring Recovery-Oriented Practice in Mental Health Facilities: A Scoping Review.Clinics and practice · 2024Article
- Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA significant number of young individuals are readmitted one or more times shortly after their first episode of psychosis. Readmission may represent a marker of psychopathological vulnerability. Our primary aim was to evaluate the impact of clinical and socio-demographic variables on readmission at 12-month follow-up. Secondly, our goal was to determine whether the use of Long-Acting Injection (LAI) antipsychotics provides notable benefits compared to oral medications in preventing subsequent readmissions. SUBJECTS AND
methods80 patients hospitalised for the first time with a diagnosis of psychotic disorder (ICD-10 criteria) were retrospectively assessed through clinical records. The mean age was 21.7 years. Patients were predominantly male (n = 62, 77.5%), and 55 subjects had at least 8 years of education. 50% of the sample was "NEET" (not in education, employment, or training).
results35 patients (43.8%) were discharged with a LAI antipsychotic, while 45 (56.2%) recieved oral antipsychotic therapy. Substance use (
conclusionOur findings underlined the importance of identifying patients at risk of readmission in order to prevent future rehospitalization and promote appropriate prevention strategies. LAIs should be considered as a first-choice treatment for patients hospitalised for FEP since they proved to be effective in preventing relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.